Race Strategic Update August 2023
SYDNEY, Aug. 9, 2023 /PRNewswire/ -- Race Oncology Limited ("Race") is pleased to provide a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene's commercial partnering and collaboration potential. Ev...
Race executes agreement with Ardena for GMP manufacturing of RC220
* Race Oncology executes agreement with leading global contract development and manufacturing organisation, Ardena as additional partner for GMP manufacturing of flagship RC220 bistanrene formulation * Ardena has a long track record of providing sterile injectable products for all stages of c...
Race executes agreement with Ardena for GMP manufacturing of RC220
* Race Oncology executes agreement with leading global contract development and manufacturing organisation, Ardena as additional partner for GMP manufacturing of flagship RC220 bistanrene formulation * Ardena has a long track record of providing sterile injectable products for all stages of c...
Race executes global license agreement with City of Hope to access FTO IP
* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...
Race executes global license agreement with City of Hope to access FTO IP
* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...
Breakthrough Chemotherapy Heart Protection Discovery for Australian Biotech
* Race Oncology's drug Zantrene shown to protect human heart muscle cells from anthracycline-induced chemotherapy death. Anthracycline's are the most used and effective anti-cancer drugs, yet they can cause serious heart damage. * The preclinical research also demonstrated Zantrene's ability t...
Zantrene® kills melanoma cancer cells that overproduce FTO
* Zantrene® at low concentrations kills high FTO producing melanoma cancer cells * Sensitivity to Zantrene® correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells * Results are highly supportive of future clinical trials in ...
Race Oncology Signs Exclusive License Agreement with BL&H Korea for the Sale of Bisantrene, an Agent for Treating Acute Myelogenous Leukemia, in South Korea
- Race Oncology is currently pursuing a 505(b)(2) regulatory pathway for Bisantrene in the U.S. - AML is the most common type of acute leukemia in adults MELBOURNE, Australia and PARIS, April 3, 2017 /PRNewswire/ -- Race Oncology, Ltd. (ASX: RAC) and BL&H Co, Ltd. announced an agreement granting...
